Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01575379
Other study ID # JDRF 17-2012-377
Secondary ID
Status Terminated
Phase Phase 4
First received April 9, 2012
Last updated December 13, 2017
Start date September 2012
Est. completion date January 31, 2014

Study information

Verified date December 2017
Source Joslin Diabetes Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recent evidence from epidemiological studies suggests that serum uric acid levels higher than average predispose diabetic patients to kidney damage. The purpose of this study is to gather preliminary information on whether lowering serum uric acid by means of oral allopurinol (a drug commonly used for the treatment of gout) can be used to prevent or delay the loss of kidney function that may accompany diabetes. The results of this study will help us design a larger study to find out whether this medication can prevent kidney problems, in particular the loss of kidney function, in people with type 1 diabetes.


Recruitment information / eligibility

Status Terminated
Enrollment 30
Est. completion date January 31, 2014
Est. primary completion date January 31, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Male or female T1D patients between 18 and 60 years of age.

- T1D diagnosed before age 35 and continuously treated with insulin within one year from diagnosis. If the onset was between ages 31 and 35, body mass index (BMI) will be required to be < 26 kg/m2 at the time of diagnosis;

- Duration of T1D = 5 years;

- Presence of microalbuminuria or moderate macroalbuminuria (at least two out of three consecutive urinary albumin excretion rates [AER] or urinary albumin/creatinine ratios (ACR) measured during the preceding two years in the 30-1500 mg/24 hr or the 30-1500 mg/g range, respectively).

- Estimated GFR (based on serum creatinine and the CKD-EPI equation) between 35 and 109 ml/min/1.73 m2 at the screening visit.

- Measured GFR between 45 and 99 ml/min/1.73 m2 at the end of the run-in period;

- Serum UA = 4.5 mg/dl at the screening visit.

- Willing to comply with schedule of events and protocol requirements.

Exclusion Criteria:

- History of gout requiring uric acid lowering therapy or xanthinuria or other indications for uric acid lowering therapy such as cancer chemotherapy or extremely high serum uric acid values (=12 mg/dl)

- Recurrent renal calculi.

- Use of urate-lowering agents within 3 months before enrollment.

- Current use of azathioprine, 6-mercaptopurine, didanosine, warfarin, tamoxifen, amoxicillin/ampicillin, or other drugs interacting with allopurinol.

- Known allergy to xanthine-oxidase inhibitors or iodine containing substances.

- HLA B*58:01 genotype (determined at the time of randomization) indicating increased risk of Stevens-Johnson syndrome in response to allopurinol.

- Renal transplant.

- Non-diabetic kidney disease as indicated by medical history and/or laboratory findings.

- SBP>160 or DBP >100 mmHg at screening or SBP>140 or DBP>90 mmHg at the end of the run-in period.

- Cancer treatment within two years before enrollment.

- History of clinically significant hepatic disease including hepatitis B or C and/or ALT (SGPT) >2.50 x ULN at screening;

- History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV);

- Hemoglobin concentration <11 g/dL (males), <10 g/dL (females) at screening.

- Platelet count <100,000/mm3 at screening.

- History of alcohol or drug abuse in the past 12 months

- Breastfeeding or pregnancy or unwillingness to be on contraception.

- Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study.

- Serious pre-existing medical problems other than diabetes, e.g. congestive heart failure, pulmonary insufficiency.

Study Design


Intervention

Drug:
Allopurinol
The allopurinol dosage will vary from 200 to 400 mg per day based on GFR. Subjects randomized to allopurinol will initially take 100 mg per day for four weeks. After that, they will be switched to 400 mg per day if their GFR is =50 ml/min/1.73 m2, 300 mg per day if their GFR is in the 25-50 ml/min/1.73 m2 range, and 200 mg per day if the GFR is in the 15-25 ml/min/1.73 m2 range. Allopurinol will be continued at this dosage throughout the study unless the GFR changes, in which case the dosage will be modified to that appropriate for the new GFR class.Subjects will be given four tablets per day to be taken orally following meals, two in the morning and two in the evening. A dosage of 100 mg will be given as a 100 mg tablet plus three placebo tablets, 200 mg as two 100 mg and two placebo tablets, 300 mg as three 100 mg and one placebo tablet, 400 mg as four 100 mg tablets. Subjects randomized to placebo will be given four placebo tablets.
Placebo
Subjects will be given four placebo (inactive) tablets per day to be taken orally following meals, two in the morning and two in the evening.

Locations

Country Name City State
Denmark Steno Diabetes Center Gentofte
United States Joslin Diabetes Center Boston Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
Alessandro Doria Steno Diabetes Center, University of Michigan, University of Minnesota - Clinical and Translational Science Institute

Countries where clinical trial is conducted

United States,  Denmark, 

References & Publications (3)

Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010 Jun;33(6):1337-43. doi: 10.2337/dc10-0227. Epub 2010 Mar 23. — View Citation

Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009 Jul;58(7):1668-71. doi: 10.2337/db09-0014. Epub 2009 May 1. Erratum in: Diabetes. 2010 Oct;59(10):2695. — View Citation

Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010 Jun;25(6):1865-9. doi: 10.1093/ndt/gfp740. Epub 2010 Jan 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Glomerular filtration rate at the end of the treatment period Glomerular filtration rate (GFR) at the end of the 2-year treatment measured by the plasma clearance of non-radioactive iohexol and adjusted for the GFR at baseline. 2 years from the date of randomization
Secondary Time to serum creatinine doubling or end stage renal disease Serum creatinine doubling is in reference to baseline creatinine values. End stage renal disease is defined as measured GFR <= 15 ml/min/1.73 m2 or start of hemodialysis or kidney transplant. From the date of randomization until the date of the first documented creatinine doubling or the first occurrence of end stage renal disease, whichever comes first, assessed up to 2 years
Secondary Urinary albumin excretion rate in the last four months of the intervention period. Median urinary albumin excretion rate during the last four months of the treatment period (measured at 84, 96, 104 weeks) adjusted for the urinary albumin excretion rate at baseline From 84 to 104 weeks from the date of randomization
Secondary Time to fatal or non-fatal cardiovascular events Fatal or non-fatal cardiovascular events are defined as a composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke, coronary artery bypass grafting, or percutaneous coronary intervention. From the date of randomization until the date of first documented event, assessed up to 2 years
Secondary Glomerular filtration rate trajectory during the treatment period Glomerular filtration rate (GFR) trajectory (as defined by the slope and intercept) during the entire treatment period estimated from quarterly serum creatinine and cystatin C measurements using the CKD-EPI SCr and the CKD-EPI SCr-SCysC equations. From the date of randomization to the end of treatment (2 years from randomization)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting NCT04084886 - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting NCT04869761 - Stem Cell Therapy for Chronic Kidney Disease Phase 1
Recruiting NCT04570735 - MRI Biomarkers in Diabetic Kidney Disease
Completed NCT03165240 - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated Phase 1
Completed NCT01968668 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) Phase 2
Completed NCT02552277 - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy Phase 2
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Terminated NCT02410005 - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL) Phase 2/Phase 3
Unknown status NCT01918488 - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT03165227 - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) Phase 1
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Phase 1/Phase 2
Not yet recruiting NCT03284996 - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus. N/A
Completed NCT03334318 - PERL Continuous Glucose Monitoring (CGM) Study
Completed NCT04380584 - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
Recruiting NCT01320345 - The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. Phase 3